Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually Stops Working
3 Articles
3 Articles
Last week, Nebraska’s former senator Ben Sasse announced that his stage 4 pancreatic cancer had developed resistance to state-of-the-art treatment. Cancer specialists were not surprised: almost all patients with pancreatic cancer who take this medication, called Daraxonrasib, end up developing resistance, said Dr. Andrew Aguirre, a pancreatic cancer specialist at the Dana-Farber Cancer Institute in Boston. The drug, approved in August, caused a …
Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually Stops Working
Researchers are asking why patients, like former Senator Ben Sasse, inevitably develop resistance to the drug daraxonrasib. Last week, the former senator from Nebraska Ben Sasse announced that his Stage 4 pancreatic cancer had developed resistance to a cutting edge treatment. Cancer specialists were … Source
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium





